Ramucirumab Plus Pembrolizumab vs Usual Care for Treatment of Stage IV or Recurrent Non-Small Cell Lung Cancer Following Immunotherapy, Pragmatica-Lung Study
SWOG Cancer Research Network
SWOG Cancer Research Network
Merck Sharp & Dohme LLC
Boehringer Ingelheim
National Cancer Institute (NCI)
National Cancer Institute (NCI)
Astellas Pharma Inc
National Cancer Institute (NCI)
Genmab
Merck Sharp & Dohme LLC
Genmab
Seagen Inc.
AstraZeneca
National Cancer Institute (NCI)
Amgen
Merck Sharp & Dohme LLC
Bayer
Arcus Biosciences, Inc.
AstraZeneca
Daiichi Sankyo
Ohio State University Comprehensive Cancer Center
Bayer
Mayo Clinic
Immutep S.A.S.
AstraZeneca
AstraZeneca
Sichuan Kelun Pharmaceutical Research Institute Co., Ltd.
Eli Lilly and Company
Pfizer
Memorial Sloan Kettering Cancer Center
Charite University, Berlin, Germany
Akeso
M.D. Anderson Cancer Center
UNICANCER
Providence Health & Services
Gilead Sciences
Hoffmann-La Roche
Werewolf Therapeutics, Inc.
Emory University
Gilead Sciences
TJ Biopharma Co., Ltd.
University of California, Davis
City of Hope Medical Center
Klus Pharma Inc.
Amgen
Eli Lilly and Company
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
ImmunityBio, Inc.
Istituto Oncologico Veneto IRCCS
GlaxoSmithKline